|
Double Medical Technology Inc. (002901.SZ) Évaluation DCF
CN | Healthcare | Medical - Devices | SHZ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Double Medical Technology Inc. (002901.SZ) Bundle
Libérez le véritable potentiel de Double Medical Technology Inc. (002901SZ) avec notre calculatrice DCF de qualité professionnelle! Ajustez les hypothèses clés, explorez divers scénarios et évaluez l'impact des changements sur l'évaluation Double Medical Technology Inc. (002901SZ) - le tout dans un modèle Excel complet.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,257.3 | 1,586.9 | 1,994.3 | 1,434.1 | 1,533.1 | 1,650.8 | 1,777.5 | 1,913.9 | 2,060.8 | 2,219.0 |
| Revenue Growth, % | 0 | 26.21 | 25.68 | -28.09 | 6.9 | 7.68 | 7.68 | 7.68 | 7.68 | 7.68 |
| EBITDA | 591.7 | 759.1 | 873.9 | 246.1 | 218.8 | 561.7 | 604.8 | 651.3 | 701.3 | 755.1 |
| EBITDA, % | 47.06 | 47.83 | 43.82 | 17.16 | 14.27 | 34.03 | 34.03 | 34.03 | 34.03 | 34.03 |
| Depreciation | 41.7 | 51.6 | 82.1 | 137.5 | 111.9 | 91.0 | 98.0 | 105.5 | 113.6 | 122.3 |
| Depreciation, % | 3.31 | 3.25 | 4.11 | 9.59 | 7.3 | 5.51 | 5.51 | 5.51 | 5.51 | 5.51 |
| EBIT | 550.0 | 707.5 | 791.9 | 108.6 | 106.9 | 470.7 | 506.9 | 545.8 | 587.6 | 632.7 |
| EBIT, % | 43.74 | 44.58 | 39.71 | 7.57 | 6.97 | 28.51 | 28.51 | 28.51 | 28.51 | 28.51 |
| Total Cash | 923.3 | 1,066.9 | 1,179.9 | 1,351.3 | 1,661.0 | 1,301.0 | 1,400.9 | 1,508.4 | 1,624.2 | 1,748.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 237.4 | 306.1 | 467.8 | 325.0 | 242.5 | 330.5 | 355.9 | 383.2 | 412.6 | 444.3 |
| Account Receivables, % | 18.88 | 19.29 | 23.46 | 22.66 | 15.82 | 20.02 | 20.02 | 20.02 | 20.02 | 20.02 |
| Inventories | 457.1 | 542.0 | 670.2 | 987.4 | 1,193.3 | 828.0 | 891.6 | 960.0 | 1,033.7 | 1,113.0 |
| Inventories, % | 36.36 | 34.16 | 33.6 | 68.85 | 77.83 | 50.16 | 50.16 | 50.16 | 50.16 | 50.16 |
| Accounts Payable | 211.1 | 179.8 | 296.3 | 345.4 | 281.6 | 282.1 | 303.7 | 327.0 | 352.1 | 379.1 |
| Accounts Payable, % | 16.79 | 11.33 | 14.86 | 24.08 | 18.37 | 17.09 | 17.09 | 17.09 | 17.09 | 17.09 |
| Capital Expenditure | -319.3 | -137.1 | -235.1 | -285.1 | -305.7 | -282.8 | -304.5 | -327.8 | -353.0 | -380.1 |
| Capital Expenditure, % | -25.39 | -8.64 | -11.79 | -19.88 | -19.94 | -17.13 | -17.13 | -17.13 | -17.13 | -17.13 |
| Tax Rate, % | 40.87 | 40.87 | 40.87 | 40.87 | 40.87 | 40.87 | 40.87 | 40.87 | 40.87 | 40.87 |
| EBITAT | 450.0 | 603.8 | 664.4 | 68.1 | 63.2 | 351.1 | 378.1 | 407.1 | 438.3 | 472.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -311.1 | 333.4 | 338.0 | -204.7 | -317.8 | 437.0 | 104.3 | 112.3 | 121.0 | 130.2 |
| WACC, % | 5.25 | 5.25 | 5.25 | 5.22 | 5.21 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 805.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 133 | |||||||||
| Terminal Value | 4,106 | |||||||||
| Present Terminal Value | 3,181 | |||||||||
| Enterprise Value | 3,986 | |||||||||
| Net Debt | -628 | |||||||||
| Equity Value | 4,614 | |||||||||
| Diluted Shares Outstanding, MM | 421 | |||||||||
| Equity Value Per Share | 10.95 |
Benefits You Will Receive
- Adjustable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Double Medical Technology Inc.’s financial information pre-loaded to kickstart your analysis.
- Automated DCF Outputs: The template automatically calculates Net Present Value (NPV) and intrinsic value for you.
- Professional and Customizable: A sleek Excel model designed to fit your valuation requirements.
- Designed for Analysts and Investors: Perfect for testing forecasts, validating strategies, and enhancing efficiency.
Key Features
- Customizable Forecast Inputs: Adjust vital parameters such as revenue growth, EBITDA %, and capital expenditures for accurate projections.
- Instant DCF Valuation: Quickly determine intrinsic value, NPV, and other financial metrics with automated calculations.
- High-Precision Accuracy: Incorporates real-world financial data from Double Medical Technology Inc. (002901SZ) for reliable valuation results.
- Effortless Scenario Analysis: Easily explore various assumptions and assess their impact on outcomes.
- Efficiency Booster: Save time by avoiding the complexities of building valuation models from the ground up.
How It Operates
- Download the Template: Gain immediate access to the Excel-based DCF Calculator for Double Medical Technology Inc. (002901SZ).
- Enter Your Assumptions: Modify the yellow-highlighted fields for growth projections, WACC, profit margins, and more.
- Automatic Calculations: The model updates the intrinsic value of Double Medical Technology Inc. (002901SZ) in real-time.
- Explore Scenarios: Test various assumptions to assess possible changes in valuation.
- Evaluate and Decide: Leverage the results to inform your investment decisions or financial evaluations.
Why Choose Double Medical Technology Inc. (002901SZ) Calculator?
- Save Time: Skip the hassle of building a DCF model from the ground up – it’s ready for immediate use.
- Enhance Accuracy: Dependable financial data and formulas minimize errors in your valuations.
- Fully Customizable: Adjust the model to fit your specific assumptions and forecasts.
- Easy to Analyze: Intuitive charts and outputs facilitate straightforward interpretation of results.
- Endorsed by Professionals: Crafted for industry experts who prioritize both precision and user-friendliness.
Who Can Benefit from Double Medical Technology Inc. (002901SZ)?
- Investors: Gain confidence in your investment choices with a robust valuation tool tailored for healthcare technology.
- Financial Analysts: Streamline your workflow with a pre-configured DCF model that can be easily customized to suit your needs.
- Consultants: Efficiently modify the template for impactful client presentations or detailed reports.
- Healthcare Enthusiasts: Enhance your knowledge of valuation methods through practical, industry-specific examples.
- Educators and Students: Leverage this resource as a hands-on learning aid in finance and healthcare-related studies.
What the Template Contains
- Pre-Filled DCF Model: Double Medical Technology Inc.’s (002901SZ) financial data preloaded for immediate use.
- WACC Calculator: Comprehensive calculations for Weighted Average Cost of Capital.
- Financial Ratios: Assess Double Medical’s (002901SZ) profitability, leverage, and efficiency.
- Editable Inputs: Modify assumptions such as growth, margins, and CAPEX to suit your scenarios.
- Financial Statements: Annual and quarterly reports to facilitate in-depth analysis.
- Interactive Dashboard: Effortlessly visualize key valuation metrics and outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.